Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready
Schafer IP Law PLLC operates in the Biotechnology & Pharmaceuticals technology area with 109 career applications. The firm has established a resolved allowance rate of 92.45 percent, indicating a strong ability to move applications to grant in this sector. This success rate provides a baseline for the firm's effectiveness in navigating the unique challenges of pharmaceutical and biological patent prosecution.
The firm currently has 3 pending office actions, representing its active workload before the USPTO. On average, the firm requires 2.08 office actions per allowance, which suggests an efficient prosecution process with relatively few rounds of rejection. This efficiency is a key characteristic of the firm's work, moving applications toward issuance with a streamlined examination cycle.
With 109 career applications and a 92.45 percent allowance rate, the firm shows consistent performance in Biotechnology & Pharmaceuticals. The 2.08 office actions per allowance metric provides a clear baseline for the expected intensity of examiner interaction for the firm's clients. These data points offer a comprehensive view of the firm's historical performance and its current active matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| DESAI, ANAND U | 1 | 78.5% | +12.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030501 | Clotting Factor Variants and Their Use | KOROTCHKINA, LIOUBOV G | 17d overdue |
| 17927078 | Lentiviral System | MATALKAH, FATIMAH KHALAF | 17d overdue |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | DESAI, ANAND U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18095484 | Engineered T Cells | MELCHIOR, JAMES RYLAND | 140d overdue |
| 18030501 | Clotting Factor Variants and Their Use | KOROTCHKINA, LIOUBOV G | 17d overdue |
| 17927078 | Lentiviral System | MATALKAH, FATIMAH KHALAF | 17d overdue |
| 18886423 | KCNV2 Variants and Their Use | REGLAS, GILLIAN CHELSEA | — |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | DESAI, ANAND U | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Expression Therapeutics, LLC | 3 |
| Artema Therapeutics, Inc. | 1 |
| Children's Healthcare of Atlanta | 1 |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1644 | 1 |
| 1638 | 1 |
| 1655 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18886423 | KCNV2 Variants and Their Use | Artema Therapeutics, Inc. | REGLAS, GILLIAN CHELSEA | §112DP | Non-Final OA | — | Pending | Sep 16, 2024 | |
| 18030501 | Clotting Factor Variants and Their Use | Children'S Healthcare Of Atlanta | KOROTCHKINA, LIOUBOV G | 1653 | §102§103§112 | Non-Final OA | 17d overdue | Pending | Apr 05, 2023 |
| 18095484 | Engineered T Cells | Expression Therapeutics, LLC | MELCHIOR, JAMES RYLAND | 1644 | §103§112DP | Non-Final OA | 140d overdue | Pending | Jan 10, 2023 |
| 17927078 | Lentiviral System | Expression Therapeutics, LLC | MATALKAH, FATIMAH KHALAF | 1638 | §102§103 | Non-Final OA | 17d overdue | Pending | Nov 22, 2022 |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | Expression Therapeutics, LLC | DESAI, ANAND U | 1655 | §102§103§112Other | Final Rejection | — | Pending | Feb 01, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial